3SBio (1530.HK) Stock Price

3SBio Price

HKEX·CLOSED
15.30CNY-0.08 (-0.51 %)
Market closed

Revenue has compounded at 29.6% per year over the past 19 years to 20.57 B CNY. Earnings per share have grown at 13.8% per year over the last 13 years. 3SBio's net margin stands at 47.9%, up from 25.9% several years earlier. 3SBio currently offers a dividend yield of about 1.63%. The payout ratio is around 5% of earnings. The dividend has grown at 20.3% per year over the past 7 years. Analysts set a median price target of 32.86 CNY, implying 114.7% above the current price. Of 18 analysts, 16 rate the stock a buy — an overall Buy consensus. The stock trades about 16% above its 52-week low.

3SBio stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of 3SBio over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how 3SBio stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing 3SBio's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

3SBio Stock Price History
Date3SBio Price
8/13/202615.30 CNY
8/12/202615.38 CNY
8/11/202615.30 CNY
8/10/202615.78 CNY
8/7/202615.49 CNY
8/6/202614.82 CNY
8/5/202614.82 CNY
8/4/202614.52 CNY
8/3/202614.24 CNY
7/31/202614.64 CNY
7/30/202615.01 CNY
7/29/202614.90 CNY
7/28/202614.81 CNY
7/27/202614.82 CNY
7/24/202614.94 CNY
7/23/202615.33 CNY
7/22/202614.94 CNY
7/21/202614.62 CNY
7/20/202614.59 CNY
7/17/202613.71 CNY
7/16/202615.48 CNY
7/15/202615.72 CNY
7/14/202615.02 CNY
7/13/202615.32 CNY
7/10/202615.69 CNY
7/9/202614.74 CNY
7/8/202615.34 CNY
7/7/202615.80 CNY
7/6/202616.84 CNY
7/3/202616.85 CNY
7/2/202616.02 CNY
6/30/202614.65 CNY
6/29/202615.00 CNY
6/26/202613.83 CNY
6/25/202613.93 CNY
6/24/202614.21 CNY
6/23/202614.23 CNY
6/22/202613.43 CNY
6/18/202614.36 CNY
6/17/202613.82 CNY
6/16/202613.94 CNY
6/15/202614.99 CNY
6/12/202614.44 CNY
6/11/202613.83 CNY
6/10/202614.27 CNY
6/9/202613.35 CNY
6/8/202613.19 CNY
6/5/202613.58 CNY
6/4/202613.84 CNY
6/3/202614.17 CNY
6/2/202614.61 CNY
6/1/202616.04 CNY
5/29/202616.02 CNY
5/28/202614.94 CNY
5/27/202616.16 CNY
5/26/202615.82 CNY
5/22/202616.66 CNY
5/21/202616.44 CNY
5/20/202616.70 CNY
5/19/202616.73 CNY
5/18/202616.81 CNY
5/15/202617.32 CNY
5/14/202617.46 CNY
5/13/202618.05 CNY
5/12/202618.71 CNY
5/11/202618.74 CNY
5/8/202619.33 CNY
5/7/202619.87 CNY
5/6/202619.11 CNY
5/5/202619.32 CNY
5/4/202619.65 CNY
4/30/202620.04 CNY
4/29/202619.25 CNY
4/28/202619.39 CNY
4/27/202619.19 CNY
4/24/202619.71 CNY
4/23/202619.18 CNY
4/22/202621.22 CNY
4/21/202621.50 CNY
4/20/202621.45 CNY
4/17/202621.88 CNY
4/16/202621.59 CNY
4/15/202621.59 CNY
4/14/202619.96 CNY
4/13/202620.68 CNY
4/10/202619.89 CNY
4/9/202619.75 CNY
4/8/202620.58 CNY
4/2/202621.98 CNY
4/1/202622.28 CNY
3/31/202619.92 CNY
3/30/202621.36 CNY
3/27/202621.10 CNY
3/26/202619.11 CNY
3/25/202619.65 CNY
3/24/202619.69 CNY
3/23/202618.86 CNY
3/20/202619.44 CNY
3/19/202620.01 CNY
3/18/202620.62 CNY
3/17/202620.06 CNY
3/16/202619.32 CNY
3/13/202618.35 CNY
3/12/202618.69 CNY
3/11/202619.27 CNY
3/10/202619.23 CNY
3/9/202617.98 CNY
3/6/202619.00 CNY
3/5/202617.37 CNY
3/4/202617.30 CNY
3/3/202617.93 CNY
3/2/202618.16 CNY
2/27/202619.30 CNY
2/26/202618.84 CNY
2/25/202619.83 CNY
2/24/202619.62 CNY
2/23/202621.03 CNY
2/20/202621.03 CNY
2/16/202620.78 CNY
2/13/202620.59 CNY
2/12/202620.62 CNY
2/11/202621.22 CNY
2/10/202621.55 CNY
2/9/202620.67 CNY
2/6/202620.18 CNY
2/5/202620.34 CNY
2/4/202620.66 CNY
2/3/202620.23 CNY
2/2/202620.27 CNY
1/30/202620.50 CNY
1/29/202621.04 CNY
1/28/202621.34 CNY
1/27/202621.18 CNY
1/26/202620.76 CNY
1/23/202621.43 CNY
1/22/202621.08 CNY
1/21/202621.99 CNY
1/20/202621.99 CNY
1/19/202622.01 CNY
1/16/202623.30 CNY
1/15/202623.72 CNY
1/14/202624.03 CNY
1/13/202624.91 CNY
1/12/202623.84 CNY
1/9/202624.33 CNY
1/8/202624.19 CNY
1/7/202624.76 CNY
1/6/202623.10 CNY
1/5/202622.86 CNY
1/2/202621.62 CNY
12/31/202521.27 CNY
12/30/202521.83 CNY
12/29/202521.99 CNY
12/24/202522.77 CNY
12/23/202523.08 CNY
12/22/202522.98 CNY
12/19/202523.01 CNY
12/18/202522.35 CNY
12/17/202522.70 CNY
12/16/202522.57 CNY
12/15/202523.08 CNY
12/12/202524.47 CNY
12/11/202524.25 CNY
12/10/202524.53 CNY
12/9/202524.76 CNY
12/8/202525.69 CNY
12/5/202526.02 CNY
12/4/202526.15 CNY
12/3/202525.78 CNY
12/2/202526.59 CNY
12/1/202527.87 CNY
11/28/202527.50 CNY
11/27/202527.64 CNY
11/26/202527.78 CNY
11/25/202526.78 CNY
11/24/202527.38 CNY
11/21/202525.81 CNY
11/20/202528.50 CNY
11/19/202528.31 CNY
11/18/202528.15 CNY
11/17/202529.12 CNY
11/14/202530.25 CNY
11/13/202529.72 CNY
11/12/202526.97 CNY
11/11/202525.67 CNY
11/10/202525.51 CNY
11/7/202525.35 CNY
11/6/202527.08 CNY
11/5/202526.66 CNY
11/4/202526.32 CNY
11/3/202527.96 CNY
10/31/202527.10 CNY
10/30/202524.35 CNY
10/28/202524.86 CNY
10/27/202525.27 CNY
10/24/202524.61 CNY
10/23/202523.86 CNY
10/22/202524.25 CNY
10/21/202525.05 CNY
10/20/202524.72 CNY
10/17/202524.88 CNY
10/16/202525.65 CNY
10/15/202524.25 CNY
10/14/202523.14 CNY
10/13/202524.47 CNY
10/10/202524.72 CNY
10/9/202525.18 CNY
10/8/202527.22 CNY
10/6/202526.30 CNY
10/3/202526.74 CNY
10/2/202527.15 CNY
9/30/202526.39 CNY
9/29/202526.52 CNY
9/26/202525.58 CNY
9/25/202527.03 CNY
9/24/202526.48 CNY
9/23/202527.20 CNY
9/22/202527.20 CNY
9/19/202526.78 CNY
9/18/202527.50 CNY
9/17/202527.43 CNY
9/16/202527.98 CNY
9/15/202528.15 CNY
9/12/202528.63 CNY
9/11/202528.12 CNY
9/10/202528.94 CNY
9/9/202531.58 CNY
9/8/202530.77 CNY
9/5/202531.37 CNY
9/4/202526.53 CNY
9/3/202527.94 CNY
9/2/202527.32 CNY
9/1/202526.36 CNY
8/29/202525.65 CNY
8/28/202524.32 CNY
8/27/202524.84 CNY
8/26/202526.48 CNY
8/25/202526.32 CNY
8/22/202527.34 CNY
8/21/202527.20 CNY
8/20/202526.80 CNY
8/19/202527.75 CNY
8/18/202528.61 CNY
Access this data via the Eulerpool API
Get Free API Key

3SBio Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
7.42 B CNY
2.12 B CNY
1.92 B CNY
Jan 1, 2022
7.97 B CNY
2.41 B CNY
2.23 B CNY
Jan 1, 2023
9.09 B CNY
2.86 B CNY
1.80 B CNY
Jan 1, 2024
10.59 B CNY
3.04 B CNY
2.43 B CNY
Jan 1, 2025
20.57 B CNY
12.26 B CNY
9.86 B CNY
Jan 1, 2026 (e)
11.75 B CNY
3.66 B CNY
2.69 B CNY
Jan 1, 2027 (e)
12.13 B CNY
3.75 B CNY
3.24 B CNY
Jan 1, 2028 (e)
11.71 B CNY
4.24 B CNY
2.93 B CNY

3SBio Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 15, 2026, 10:06 AM
 
REVENUEB CNY
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB CNY
EBITB CNY
EBIT MARGIN%
NET INCOMEB CNY
NET INCOME GROWTH%
DIV.CNY
DIV. GROWTH%
SHARESB
20132014201520162017201820192020202120222023202420252026e2027e2028e
1.021.311.943.254.345.336.186.507.427.979.0910.5920.5711.7512.1311.71
33.4629.2047.9567.2333.5022.7616.035.0614.217.4813.9516.5394.29-42.893.23-3.41
90.4692.2485.5585.6481.8980.8682.5980.9782.6682.6984.9885.9592.3892.3892.3892.38
0.921.211.662.783.554.315.115.266.136.597.729.1019.0010.8511.2010.82
0.320.440.561.061.341.421.551.702.122.412.863.0412.263.663.754.24
31.7633.5628.6032.4830.9426.6525.1126.1628.6230.1631.4528.6759.5931.1430.9336.20
0.110.340.610.831.091.481.130.971.922.231.802.439.862.693.242.93
-5.93205.4180.2435.5231.2836.52-23.79-14.1597.6316.00-19.1434.94305.93-72.7720.82-9.83
–––––0.07–––0.200.100.250.250.300.360.43
––––––––––-50.00150.00–20.0020.0019.44
1.941.942.602.582.742.742.542.542.772.622.442.502.492.492.492.49
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales 3SBio generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue 3SBio retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare 3SBio's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares 3SBio has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against 3SBio's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

3SBio stock margins

The 3SBio margin analysis displays the gross margin, EBIT margin, as well as the profit margin of 3SBio. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for 3SBio.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
82.67 %
28.62 %
25.87 %
Jan 1, 2022
82.69 %
30.17 %
27.93 %
Jan 1, 2023
84.98 %
31.45 %
19.82 %
Jan 1, 2024
85.95 %
28.67 %
22.95 %
Jan 1, 2025
92.38 %
59.59 %
47.93 %
Jan 1, 2026 (e)
92.38 %
31.14 %
22.86 %
Jan 1, 2027 (e)
92.38 %
30.94 %
26.75 %
Jan 1, 2028 (e)
92.38 %
36.20 %
24.98 %

3SBio Stock Revenue, EBIT, Earnings per Share

The 3SBio earnings per share therefore indicates how much revenue 3SBio has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
2.67 CNY
0.77 CNY
0.69 CNY
Jan 1, 2022
3.04 CNY
0.92 CNY
0.85 CNY
Jan 1, 2023
3.72 CNY
1.17 CNY
0.74 CNY
Jan 1, 2024
4.23 CNY
1.21 CNY
0.97 CNY
Jan 1, 2025
8.27 CNY
4.93 CNY
3.97 CNY
Jan 1, 2026 (e)
4.76 CNY
1.47 CNY
1.09 CNY
Jan 1, 2027 (e)
4.92 CNY
1.51 CNY
1.32 CNY
Jan 1, 2028 (e)
4.75 CNY
1.71 CNY
1.19 CNY

3SBio business model & stock analysis

3SBio Inc. is a biopharmaceutical company from China that specializes in the research, development, manufacturing, and marketing of biological products. It was founded in 1993 in Shenyang, a city in northeast China, and its headquarters are now in Beijing. 3SBio's business model is based on the development and manufacturing of biopharmaceuticals that are used to treat cancer, autoimmune diseases, and other serious illnesses. The company focuses on biological medicines such as proteins, antibodies, and peptides that are produced using genetic technology. 3SBio operates a wide range of business sectors, including the manufacturing and sale of biopharmaceutical products, the manufacturing and sale of generics and biosimilar products, and research and development in the biotechnology field. The company also has several subsidiaries and joint ventures, including 3SBio International Holding, Sunshine Guojian Pharmaceutical, and Target Pharma. A well-known product of 3SBio is erythropoietin (EPO), which is used in the treatment of anemia. The company also has a portfolio of other biopharmaceutical products that are used to treat cancer, autoimmune diseases, and other serious illnesses. The history of 3SBio goes back to 1993 when it was founded as Shenyang Sunshine Pharmaceutical. In 2001, the company was renamed "Shenyang Sunshine Pharmaceutical Co. Ltd. 3S Bio" and focused on biological therapy. In 2007, the company successfully listed on the Hong Kong Stock Exchange and received the name 3SBio. In 2013, the company was privatized and acquired by a consortium of Chinese investment companies. 3SBio has a strong presence in China and is also expanding into international markets. The company has distribution partnerships in Asia, Europe, and North America, and plans to enter more markets. Overall, 3SBio is a leading company in China in the field of biopharmaceuticals that focuses on the treatment of serious illnesses. The company aims to be a leader in research and development, as well as in the manufacturing and sale of innovative products, and to expand its presence in global markets.

3SBio SWOT Analysis

Strengths

  • Strong expertise and experience in the biopharmaceutical industry.
  • Well-established brand recognition and reputation for quality products.
  • Diversified product portfolio catering to various therapeutic areas.
  • Robust research and development capabilities driving innovation.

Weaknesses

  • Dependence on a limited number of key pharmaceutical products.
  • Relatively small market share compared to larger competitors.
  • Limited global presence, primarily focused on the Chinese market.

Opportunities

  • Growing demand for biopharmaceutical products in emerging markets.
  • Potential expansion into new therapeutic areas or development of novel drugs.
  • Strategic partnerships and collaborations to access new markets or technologies.

Threats

  • Intense competition from both domestic and international pharmaceutical companies.
  • Stringent regulatory requirements and increasing compliance standards.
  • Economic uncertainties and volatile market conditions impacting sales and investment.

3SBio Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

3SBio historical P/E ratio, EBIT multiple, and P/S ratio

3SBio annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

3SBio shares outstanding

The number of shares of 3SBio was 2.49 B in 2025. This indicates how many shares 3SBio is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
2.77 B Stocks
Jan 1, 2022
2.62 B Stocks
Jan 1, 2023
2.44 B Stocks
Jan 1, 2024
2.50 B Stocks
Jan 1, 2025
2.49 B Stocks
Jan 1, 2026 (e)
2.49 B Stocks
Jan 1, 2027 (e)
2.49 B Stocks
Jan 1, 2028 (e)
2.49 B Stocks

3SBio Dividend History

5 years of dividend payments

YearAnnual DividendYoY ChangePayments
20250.25CNY 0.0%1×
Jul 21, 20250.25CNY 0.0%1/1
20240.25CNY↑ 150.0%1×
20230.10CNY↓ 50.0%1×
20220.20CNY↑ 192.0%1×
20180.07CNY—1×

3SBio dividend history and estimates

In 2025, 3SBio paid a dividend amounting to 0.25 CNY. Dividend means that 3SBio distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2018
0.07 CNY
0.00 CNY
Jan 1, 2022
0.20 CNY
0.00 CNY
Jan 1, 2023
0.10 CNY
0.00 CNY
Jan 1, 2024
0.25 CNY
0.00 CNY
Jan 1, 2025
0.25 CNY
0.00 CNY
Jan 1, 2026 (e)
0.00 CNY
0.30 CNY
Jan 1, 2027 (e)
0.00 CNY
0.36 CNY
Jan 1, 2028 (e)
0.00 CNY
0.43 CNY

3SBio dividend payout ratio

In 2025, 3SBio had a payout ratio of 5.42%. The payout ratio indicates the percentage of the company's profits that 3SBio distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
13.08 %
Jan 1, 2022
20.27 %
Jan 1, 2023
11.66 %
Jan 1, 2024
22.14 %
Jan 1, 2025
5.42 %
Jan 1, 2026 (e)
27.56 %
Jan 1, 2027 (e)
27.37 %
Jan 1, 2028 (e)
36.42 %

Current 3SBio forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.40 %
Buy
88.89 % (16)
Hold
11.11 % (2)
Sell
0.00 % (0)
12M Price Target
32.86
Last Price
15.30
Currency
CNY
12M Return Potential
114.72 %
LTM Return
0 %

EESG©

Eulerpool ESG Scorecard© for the 3SBio stock

89/100
96
Environment
99
Social
71
Governance
E

Environment

20
Scope 1 - Direct Emissions13,304.07
Scope 2 - Indirect emissions from purchased energy53,966.8
Scope 3 - Indirect emissions within the value chain20,793,853
Total CO₂ emissions67,270.87
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees53.183
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

3SBio shareholder structure

% Name
19.32916%
Century Sunshine Ltd.
Century Sunshine Ltd.
2.28932%
Lou (Jing)
Lou (Jing)
2.26331%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
1.47658%
Dimensional Fund Advisors, L.P.
Dimensional Fund Advisors, L.P.
1.26256%
Pfizer Inc
Pfizer Inc
0.98859%
Su (Dongmei)
Su (Dongmei)
...

3SBio Beneficial Ownership Filings (SEC 13D/G)

Free Float
74.0%
Float Shares
-
Shares Outstanding
-

3SBio Executives and Management Board

12 members · avg. age 53 · 42 % women

JL

Mr. Jing Lou (62)

Executive Chairman of the Board, President, Chief Executive Officer · since 2006

8.12 M CNY

Management

DS

Ms. Dongmei Su (55)

Senior Vice President, General Manager - Shenyang Sunshine, Executive Director

1.46 M CNY
XH

Mr. Xiang He (41)

Chief Financial Officer

–
ZJ

Mr. Zheng Jin (44)

General Manager - Shenyang Sunshine

–
SL

Ms. Siu Kuen Lai

Company Secretary · since 2022

–

Board of Directors

JZ

Ms. Jiaoe Zhang (62)

Non-Executive Director

406,000.00 CNY
JN

Mr. Joo Yeow Ng (60)

Non-Executive Independent Director

274,000.00 CNY
TP

Mr. Tianruo Pu (57)

Independent Non-Executive Director

274,000.00 CNY
HY

Ms. Hoi Ti Heidi Yang (55)

Non-Executive Independent Director

274,000.00 CNY
YX

Mr. Yong Xu (60)

General Manager, Director of Sciprogen

–
AY

Mr. An Yu (42)

General Manager, Executive Director of Sunshine Mandi

–

Frequently asked questions about 3SBio

3SBio Inc operates as a leading biotechnology company. The business model of 3SBio Inc revolves around the research, development, manufacturing, and commercialization of biopharmaceutical products. The company focuses on developing innovative therapies to address unmet medical needs, particularly in the fields of oncology, nephrology, and autoimmune diseases. By leveraging their expertise in biologics and in-house manufacturing capabilities, 3SBio Inc aims to deliver high-quality and affordable medicines to patients worldwide. With a commitment to advancing healthcare, 3SBio Inc continues to invest in R&D efforts and strategic partnerships, aiming to improve patient outcomes and enhance their market presence.

3SBio Inc is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of 3SBio Inc in the market include companies such as Johnson & Johnson, Pfizer Inc, Novartis International AG, Amgen Inc, and Roche Holding AG.

3SBio Inc is a leading biotechnology company specializing in the research, development, and manufacturing of innovative biopharmaceutical products. Founded in 1993, the company has a rich history in the biotech industry. With its headquarters in China, 3SBio Inc has expanded globally and gained recognition for its expertise in therapeutic areas including nephrology, oncology, and immunology. The company is committed to improving patient outcomes through the development of high-quality, life-saving medications. 3SBio Inc has established itself as a trusted name in the biopharmaceutical sector, delivering innovative solutions to address unmet medical needs and improve the quality of life for patients worldwide.

3SBio Inc has achieved several significant milestones. The company successfully completed its initial public offering (IPO) on the Hong Kong Stock Exchange in 2015, marking a major milestone in its history. Furthermore, 3SBio Inc has seen remarkable growth and success in the biopharmaceutical industry, particularly in the development and commercialization of innovative medicines. They have obtained regulatory approvals for various products, expanded their product portfolio, and established strategic partnerships to enhance their market presence. The company's dedication to research and development has also resulted in numerous scientific achievements and breakthroughs. Overall, 3SBio Inc has demonstrated consistent progress and remains a leading player in the biopharmaceutical sector.

3SBio Inc is primarily present in China and the United States.

3SBio Inc represents a commitment to innovation, integrity, and excellence in the biopharmaceutical industry. The company values putting patients first and developing high-quality therapeutic solutions. With a focus on research and development, 3SBio Inc is dedicated to discovering, developing, and commercializing innovative biopharmaceutical products. The company's corporate philosophy centers around offering effective and affordable treatments to improve patients' lives. By staying true to their core values, 3SBio Inc aims to make a positive impact on healthcare and contribute to the well-being of individuals worldwide.

Analysts currently set an average price target of 33.39 CNY for the 3SBio stock (median: 32.86 CNY), implying +118.2 % versus the latest price. The consensus is based on 18 analyst ratings.

3SBio Analyst Price Targets 2026

18 analysts currently rate the 3SBio stock: 16 recommend buying, 2 holding and 0 selling. For 2026, analysts expect 3SBio to generate revenue of 11.75 B CNY and earnings per share of 1.08 CNY.

3SBio Analyst Price Targets 2026

Converted at the current exchange rate, the 3SBio share trades at 1.96 EUR (15.30 CNY).

The 3SBio share (1530.HK) is listed on 5 stock exchanges, including: Frankfurt (83B.F), München (83B.MU), Düsseldorf (83B.DU).

The Chinese company 3SBio Inc is a leading company in the biopharmaceutical industry, specializing in the development, manufacturing, and marketing of biological drugs. 3SBio focuses on the areas of oncology, immunology, nephrology, and infectious diseases. The main products of 3SBio include biosimilars of innovative drugs such as rituximab, enoxaparin, adalimumab, darbepoetin alfa, pegaspargase, and etanercept. Biosimilars are biologically manufactured drugs that have similar active ingredients as original biologics and thus provide a more cost-effective alternative. 3SBio has the largest market share for biosimilars in China and continually expands its portfolio. In addition to biosimilars, 3SBio also offers innovative biological drugs. One example is Tpiao, a recombinant human thrombopoietin receptor agonist. It is used to treat thrombocytopenia in patients with hepatitis B or hepatitis C infections. Another important area for 3SBio is nephrology. The company has various products in its portfolio that are used to treat kidney diseases. These include, for example, the erythropoiesis-stimulating agent (ESA) ferumoxytol, which is used to treat iron deficiency anemia in chronic kidney disease, as well as binodenoson, an adenosine receptor agonist used for diagnostic imaging of kidney diseases. The business model of 3SBio Inc is based on the acquisition of promising technologies, its own research and development work, and the manufacturing and marketing of biological drugs. The company works closely with regulatory authorities and health organizations to achieve fast market approval for its products. An important aspect is also international distribution. 3SBio strategically enters growth markets in Asia, especially in China, and expands into other parts of the world. Through partnerships with other companies and the acquisition of firms in the biopharmaceutical industry, 3SBio continuously expands its value chain and its portfolio. Overall, 3SBio pursues a diversified business model based on the utilization of synergies in the areas of research, development, manufacturing, and marketing of biological drugs. By utilizing biosimilars and innovative active ingredients, the company has achieved high competitiveness and is on a path of expansion.

The expected revenue of 3SBio is 11.75 B CNY. This figure is based on current financial data and reflects the company's business performance.

The expected profit of 3SBio is 2.69 B CNY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of 3SBio is currently 14.17. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the 3SBio stock.

The price-to-sales ratio (P/S) of 3SBio is currently 3.24. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the 3SBio stock.

The Eulerpool Quality Score for 3SBio is 8/10.

The ISIN of 3SBio is KYG8875G1029. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of 3SBio is A14T7Q. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of 3SBio is 1530.HK. The ticker symbol is used to trade 3SBio shares on the stock exchange.

Over the past 12 months, 3SBio paid a dividend of 0.25 CNY . This corresponds to a dividend yield of about 1.63 %. For the coming 12 months, 3SBio is expected to pay a dividend of 0.36 CNY.

The current dividend yield of 3SBio is 1.63 %.

3SBio pays a dividend, distributed in the months of , , , .

3SBio paid dividends every year for the past 4 years.

For the upcoming 12 months, dividends amounting to 0.36 CNY are expected. This corresponds to a dividend yield of 2.35 %.

3SBio is assigned to the 'Health' sector.

To receive the latest dividend of 3SBio from amounting to 0.25 CNY, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, 3SBio distributed 0.25 CNY as dividends.

The dividends of 3SBio are distributed in CNY.

All fundamentals and in-depth analysis of 3SBio

Our stock analysis for 3SBio stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of 3SBio. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

3SBio Stock
3SBio Revenue→
3SBio Stock
3SBio Net Income→
3SBio Stock
3SBio P/E→
3SBio Stock
3SBio P/S→
3SBio Stock
3SBio EBIT→
3SBio Stock
3SBio Dividend→
3SBio Stock
3SBio Directors Dealings→
3SBio Stock
3SBio Stocks→
3SBio Stock
3SBio Market capitalization→
3SBio Stock
3SBio Debt→
3SBio Stock
3SBio Liabilities→
3SBio Stock
3SBio Equity→
3SBio Stock
3SBio AAQS→
3SBio Stock
3SBio Employees→
3SBio Stock
3SBio ROE→
3SBio Stock
3SBio ROA→
3SBio Stock
3SBio ROCE→
3SBio Stock
3SBio News→
3SBio Stock
3SBio Analyst Price Targets→

Health Stocks

4Basebio3D Medicines4D Molecular Therapeutics3D Global Biotech4DMedical3-D Matrix60 Degrees Pharmaceuticals2cureXA Plus Biotechnology Co21st NorthAap Implantate1CMAll Stocks A–Z →